January 28, 2019
Law360 has named Latham & Watkins as a Life Sciences Practice Group of the Year for 2018. In the publication’s profile story, Law360 highlighted that Latham’s “… success is based on being able to provide a wide range of life sciences services, including corporate, transnational and intellectual property, as dictated by their clients' needs.”
John Manthei, Global Chair of Latham’s Health Care and Life Sciences Practice, added that Latham is “structured in the way the clients demanded, in that each one of the core areas where health care and life sciences needs are, we're able to both domestically and internationally service those needs in a very coordinated way."
Latham’s Life Sciences team continues to shepherd a number of precedent setting wins. One example Law360 mentioned was the case of Alvogen v State of Nevada. After receiving notice on a Saturday that Alovgen’s drug midazolam would be used in an execution that Wednesday, the firm was able to secure a last-minute injunction, and later won the case, that prevented the state from using the drug on the basis that the State of Nevada could not have legally obtained the drug for this use. This was the first time a drugmaker was able to prevent its product from being used in an execution.
Latham’s work for Eagle Pharmaceuticals was also recognized in the Law360 article, particularly for the firm’s efforts to ensure that orphan drug exclusivity was granted for its novel chemotherapy drug, BENDEKA. Originally, the FDA claimed that BENDEKA, which treats rare forms of blood cancers, was ineligible to receive orphan drug exclusivity, but after a lawsuit challenged the basis of the FDA claim in this matter, a D.C. federal judge overturned the FDA’s decision and awarded the period of exclusivity to Eagle.
The firm’s robust life sciences capabilities were further honored with recognition for three major corporate transactions in the industry, including the firm‘s representation of Amneal Pharmaceuticals LLC in a merger with Impax Laboratories, to form the fifth largest generic-drug company in the U.S. In addition, leading the Guardant Health US$238 million initial public offering; and in advising on the strategic collaboration between Celgene Corp. and Prothena Corp LPC where Latham advised Prothena, a clinical stage biotech company working on treatments for neurodegenerative disorders.